Dow AgroSciences CEO Antonio Galindez told investors Wednesday morning that the company plans to launch five products
by 2013 that could increase annual revenue by $800 million.
A report set to be released Wednesday by local life sciences industry group BioCrossroads says Indiana companies providing
contract pharmaceutical research and manufacturing services are weathering the economic downturn and are growing.
The Indianapolis area is home to myriad unsung entrepreneurs who run interesting companies, make money and create good jobs.
Here are some of them.
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009. That trend hit Indianapolis,
but the rest of the state actually saw an increase.
Indianapolis-based Dow AgroSciences said Tuesday it posted a profit of $69 million in the fourth quarter, down 19 percent
from the prior year because of increased research and development spending and higher administrative expenses. Revenue was
up 17 percent.
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
The awards are meant to showcase Indiana’s high-tech success stories and raise the profile of the tech community.
Indianapolis-based Dow AgroSciences LLC has sued Cooper Industries Plc in an effort to clarify its rights to make a canola-based
fluid used in electrical transformers.
Jim Pearson knows a thing or two about raising money from venture capitalists. And he has some advice for BioCrossroads:
Teach entrepreneurs the value of money.
More than half of the venture capital fund’s original investors took a pass on its $58 million successor, the newly launched
INext.
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
The new INext fund is the successor to the $73 million Indiana Future Fund, which the life science initiative raised in 2003.
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
Cold storage might become a hot business for a building contractor.
A new task force is charged with making recommendations for development of the city’s downtown certified technology
park.
The Indiana-based orthopedic implant maker plans to use the proceeds to pay down debt and for general corporate purposes.
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
